Navigation Links
Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
Date:6/18/2008

WINSTON-SALEM, N.C., June 18 /PRNewswire/ -- Pilot Therapeutics Holdings, Inc. today announced the relaunch of Pilot Therapeutics as Gene Smart(TM) Health.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080618/CLW006LOGO )

As an innovator in gene-based nutrition, Gene Smart(TM) Health uniquely combines breakthrough scientific innovation and an in-depth understanding of the health, food, nutrition, and wellness markets to create major new businesses that empower individuals to take care of their health and live life abundantly.

"Through the scientific leadership of our Founder and Chief Science Officer, Dr. Floyd 'Ski' Chilton, we are at the forefront in understanding relationships between nutrition, gene expression, inflammation and health," said Ross Consaul, CEO of Gene Smart(TM) Health.

The company is developing three distinct businesses: Gene Smart(TM) Therapeutics, Gene Smart(TM) Ingredients, and Gene Smart(TM) Wellness.

"Our world's health crisis, with unprecedented levels of obesity accompanied by dramatic increases in chronic inflammatory conditions, is a bold call for action for science-based innovations in prevention, nutrition and wellness," said Keith Wakeman, President of Gene Smart(TM) Health. "Revolutionary advances in our understanding of both nutrition and the human genome provide us with new tools to begin to address these enormous problems."

Gene Smart(TM) Therapeutics is developing a pipeline of over the counter (OTC) products, functional foods & beverages, and veterinary medical foods to prevent and treat chronic inflammatory conditions; Gene Smart(TM) Ingredients creates science-based nutrition ingredients to improve the healthfulness of the world's food supply; and Gene Smart(TM) Wellness integrates prevention into healthcare through clinically validated wellness programs.

"This relaunch is an important mile
'/>"/>

SOURCE Gene Smart Health
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
2. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
3. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
4. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
5. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...LIN, Mass., Nov. 26 PLC ... today that it has received full approval from the....S. pivotal trial to study the effectiveness of th...therapy in the prevention of Contrast-Induced Neph...C,s request to expand their investigation from the...
(Date:11/25/2008)...e-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (Na...d on,innovative oncology therapies, announced tod...es for its preclinical research programs in order ...e clinical development of picoplatin,its lead pr...cialization of,picoplatin in the treatment of sma...
(Date:11/24/2008)...o,s Pizza (NYSE: DPZ ), the,recognized world le...gh for,the kids of St. Jude Children,s Research H... campaign. Domino,s customers will have the opport...benefit the children of St. Jude.,Donations can b...ng online at, www.dominos.com . The campaign begi...
(Date:11/24/2008).../ -- Schering-Plough Corporation (NYSE: SGP ) to...tive adenosine2a receptor antagonist, met the prim...atients suffering from moderate to severe Parkinso...normal involuntary movements (dyskinesias). The t... 2008 R&D Update meeting being hosted for anal...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 1Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 2Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 3ATV Injuries on the Rise 6905 1ATV Injuries on the Rise 6905 2ATV Injuries on the Rise 6905 3Environmental exodus 1331 1Environmental exodus 1331 2Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 1Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 2
...sults Presented At ASCO -- , CHICAGO – June ... interferon alfa-2b in stage III melanoma had a,si...vival (RFS),according to the results of the large...stage III melanoma. Results of the Phase,III study...h and,Treatment of Cancer (EORTC) and supported by...
...007 - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmac..., today provided highlights of data presentations ...Oncology (ASCO) Annual,Meeting. Dacogen (decitabin...ncluding the presentation of efficacy data in olde...nd activity,observed in patients with refractory a...
Other Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
(Date:12/1/2008)...wire-USNewswire/ -- In recognition of World AIDS D...ching a mobile texting campaign to raise money for... a program of the Safe Blood for Africa Foundation...e million lives in Africa by 2011 by working in re...cal training. , , OMALI will be collecting...
(Date:12/1/2008)...RNewswire/ -- TOMS Shoes, the philanthropic,footw...e at TOMSshoes.com,encouraging people to Spend L...s, from November 20th through December 20th, TOMS ...irs of shoes to children in Ethiopia suffering,fr... by wearing shoes. By,purchasing a pair of shoes ...
(Date:12/1/2008)...rom U-M physician include economical options , ...SNewswire/ -- A bottle of cologne, a new pair of p...s to buy and wrap for the upcoming holiday season....y and beneficial to a loved one? Why not give the ... the holidays can be challenging, and this year, m...
(Date:12/1/2008)...swire/ -- TorreyPines Therapeutics, Inc.,(Nasdaq:... of NGX426, an,AMPA/kainate-type glutamate recept...ficant reduction in spontaneous pain, hyperalgesia...(pain resulting from normally non-painful stimuli ...ermal injections of capsaicin in,a human experime...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5
...terday about a surgeon Dr Jerome Blanchard who had.../ her with only a diseased one. The disciplinary...hurry removed the wrong kidney from a patient and ...did not bother to read her medical notes. Dr Jerom...
... price tag attached to it.Look at the United State...ealth and opportunity to its people;// but at a co...are 30% Americans who areover-weight or grossly ob...beingmade by China is going to land the country in...
...ude as many patients in the chronic disease manage...ter for Health Khaw Boon Wan who was addressing he...at chronic diseases are major causes of death and ...he past," Khaw said, adding that prompt treatment ...
...everages by the FDA (Food and Drug Administration)...nce of benzene//, a carcinogen in much higher amou...inking water. FDA had alerted these companies, an...te the soft drinks or had already done so. Though ...
Other Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:The Price Paid for New Lifestyle 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: